RNA polymerase III-related hypomyelinating leukodystrophy (POLR3-HLD; MIM: 607694, 614381, 616494), or 4H leukodystrophy, is one of the most common hypomyelinating leukodystrophies, typically associated with the cardinal clinical features of hypogonadotropic hypogonadism and hypodontia.^[@R1][@R2][@R3]^ POLR3-HLD commonly presents in childhood, with motor delay or regression, prominent cerebellar features, mild pyramidal signs, and variable cognitive involvement.^[@R1]^ Typical brain MRI pattern includes diffuse hypomyelination with relative preservation (T2 hypointensity) of the anterolateral nucleus of the thalamus, globus pallidus, dentate nucleus, optic radiations, and pyramidal tracts in the posterior limb of the internal capsule, along with cerebellar atrophy and thinning of the corpus callosum.^[@R4][@R5][@R6]^

POLR3-HLD is caused by biallelic pathogenic variants in *POLR3A, POLR3B*, *POLR1C*, or *POLR3K*, which encode subunits of RNA polymerase III (POLR3), an enzyme responsible for transcription of several noncoding RNAs (nc-RNAs), including transfer RNAs (tRNAs), 5S ribosomal RNA, U6 small nuclear RNA, 7S RNAs, and other small nucleolar RNAs.^[@R7][@R8][@R15]^ The precise mechanism underlying the pathogenesis of hypomyelination remains to be fully elucidated; 2 main mechanistic hypotheses include (1) defects in transcription capability of POLR3 causing disruptions in tRNA levels, thereby altering global translation during myelination, which require large production of essential myelin proteins, or (2) impairments in specific POLR3-transcribed nc-RNAs required for myelin development.^[@R7],[@R10],[@R16]^

Here, we expand the phenotypic spectrum of POLR3-HLD through description of clinical, radiologic, and molecular features of six patients with an extremely severe phenotype and present functional and neuropathologic investigations on one patient.

Methods {#s1}
=======

Patients and study design {#s1-1}
-------------------------

An international cross-sectional study was performed between 2016 and 2019, including a retrospective chart review of 6 patients (P1-6) from 5 families with atypical phenotypes identified from a repository of genetically proven POLR3-HLD patients.

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

This research was approved by the Montreal Children\'s Hospital and McGill University Health Center Research Ethics Boards (11-105-PED; 2019-4972). Informed consent was obtained from all patients or legal guardians.

Neuroradiology {#s1-3}
--------------

Brain MRI review was performed on latest available scans by L.G. and G.B. based on previously published criteria for hypomyelination and POLR3-HLD imaging characteristics.^[@R1],[@R5],[@R6],[@R17][@R18][@R19]^ The earliest studies were also analyzed when available. Only one study was available for P5 and P6.

Neuropathology {#s1-4}
--------------

Neuropathologic investigations were performed on postmortem brain tissue from P2; details are provided in supplemental methods ([links.lww.com/NXG/A257](http://links.lww.com/NXG/A257)).

Genetic analysis {#s1-5}
----------------

Variants in *POLR3A* were identified by exome sequencing using genomic DNA extracted from blood samples, according to standard protocols. Variants were validated by Sanger sequencing and analyzed for familial segregation when DNA was available.

Cell culture and cycloheximide treatment {#s1-6}
----------------------------------------

To evaluate the presence of nonsense mediated decay (NMD), fibroblasts derived from P2 were subjected to treatment with cycloheximide. Experimental details are described in supplemental methods ([links.lww.com/NXG/A257](http://links.lww.com/NXG/A257)).

Western blot {#s1-7}
------------

Immunoblots were performed using brain tissue protein extracts of P2 and an age/sex-matched control. Detailed protocols are outlined in supplemental methods ([links.lww.com/NXG/A257](http://links.lww.com/NXG/A257)).

Data availability {#s1-8}
-----------------

Data supporting this study\'s findings are available on reasonable request. Raw data from participants (i.e., raw genetic data and MRI data sets) are not made publicly available to protect patient privacy.

Results {#s2}
=======

Clinical characteristics {#s2-1}
------------------------

Patients 1--6 (P1-6) presented during infancy, between ages 1 and 3 months, with prominent feeding difficulties and failure to thrive. They exhibited severe developmental delay and motor regression before age 1 year. None achieved independent walking. Clinical characteristics are summarized in [table 1](#T1){ref-type="table"} and table e-1 ([links.lww.com/NXG/A257](http://links.lww.com/NXG/A257)).

###### 

Clinical, MRI, molecular, and pathologic features associated with the typical and severe POLR3-related leukodystrophy phenotypes

![](NG2019012377t1)

Of the 6 patients, 3 (3/6, 50%) had laryngomalacia and 2 underwent supraglottoplasty. All had dysphagia and required enteral tube feeding, with 5 (5/6, 83%) requiring a gastrostomy or gastrojejunostomy tube placement between ages 5 and 15 months. Four patients (4/6, 67%) developed severe respiratory insufficiency, and 3 required supplemental oxygen and/or noninvasive respiratory support between ages 5 and 15 months, with 1 later having a tracheostomy at age 13 months. In addition, 2 patients (2/6, 33%) had suspected paroxysmal episodes of dysautonomia, with excessive sweating and retching.

Non-neurologic features typical of POLR3-HLD included delayed dentition (3/6, 50%) and ophthalmologic abnormalities, including hyperopia and cortical visual impairment (4/6, 67%). All patients were too young for hypogonadotropic hypogonadism to be appreciated.

Neurologic examination revealed acquired microcephaly in 4 patients (4/6, 67%). Five (5/6, 83%) had a combination of axial hypotonia and upper motor neuron signs (spasticity and/or hyperreflexia) in the limbs. Generalized dystonia and/or chorea was seen in all patients. Restricted upgaze and abnormal saccades were occasionally noted. Two patients exhibited hypomimia.

Progressive decline and respiratory complications led to the death of P1, P2, and P3 before age 2 years and P4 at age 3 years. P5 and P6 are alive and currently aged 5 and 3 years, respectively.

Radiologic characteristics {#s2-2}
--------------------------

Brain MRI characteristics of P1-6 are summarized in [table 2](#T2){ref-type="table"} and [figure 1](#F1){ref-type="fig"}, which compares a typical POLR3-HLD MRI to P3. All 10 studies available for the 6 patients showed evidence of insufficient myelin deposition, but criteria for diffuse hypomyelination were not met ([figure 1, E--K](#F1){ref-type="fig"}).^[@R6],[@R17]^ Overall, there was more myelin than usually seen in POLR3-HLD and additional distinctive MRI characteristics. T2 hyperintensity of the hilus of the dentate nucleus, associated with T2 hypointensity (preserved myelination) of the dentate nucleus itself and peridentate region, was seen in all studies ([figure 1F](#F1){ref-type="fig"}). In 9/10 studies (90%), the posterior brainstem exhibited similar features, with T2 hyperintensity (decreased myelin content) of the posterior medulla, posterior-inferior pons, and posterior aspect of the middle cerebellar peduncles, in a pattern suggestive of axonal degeneration ([figure 1, F, I, and J](#F1){ref-type="fig"}). The latest imaging studies of 2 patients (2/6, 33%), obtained at ages 10 and 11 months, also revealed T2 hyperintensity of the red nucleus ([figure 1K](#F1){ref-type="fig"}). In addition, 8/10 studies (80%) revealed abnormal signal of the lentiform nuclei, which appeared hyperintense on T2 sequences compared with gray matter and isointense to unmyelinated white matter. The same 8 studies also showed atrophy of the thalami ([figure 1G](#F1){ref-type="fig"}). The 2 scans without these findings were the 2 earliest studies (P2, age 2 months; P3, age 3 months); however, follow-up MRIs showed that these changes developed over time. Basal ganglia atrophy was seen only in the 5 latest scans obtained between ages 10 and 15 months. Cerebellar atrophy was not seen in any studies; however, mild to severe supratentorial atrophy was present in all cases ([figure 1, G--H](#F1){ref-type="fig"}). No signs of pituitary involvement were noted.

###### 

MRI features of patients with the severe POLR3-related leukodystrophy phenotype

![](NG2019012377t2)

![MRI characteristics\
Sagittal T1-weighted (A, E) and axial T2-weighted (B--D, F--K) images. (A--D) Typical POLR3-HLD; MRI obtained at age 6 years. Hypomyelination with relative preservation (T2 hypointensity) of the dentate nucleus (red arrow; B), anterolateral nucleus of the thalamus (double-lined arrow; C), optic radiations (arrowhead; C), globus pallidus, and corticospinal tracts in the posterior limb of the internal capsule (not shown). Thinning of the corpus callosum and cerebellar atrophy are also seen. (E--K) Severe phenotype; MRI of patient 3 obtained at age 10 months. Mild insufficient myelin deposition, not meeting the criteria for diffuse hypomyelination. Loss of myelin (T2 hyperintensity) in the posterior brainstem (red arrows; F, I, J), red nucleus (red dashed arrow; K), and hilus of the dentate nucleus (double-lined arrow; F). Abnormal signal of the lentiform nucleus (arrowhead; G). Supratentorial atrophy (G--H) and diffuse atrophy of the basal ganglia and thalami (G) are also seen.](NG2019012377f1){#F1}

Neuropathology {#s2-3}
--------------

Preserved brain tissue of P2, who died at age 13 months from respiratory complications, was subjected to neuropathologic study ([figure 2](#F2){ref-type="fig"}). The brain weighed 777 g, below expected brain weight and comparable to typical weight at age 8 months.^[@R20]^ Macroscopic examination revealed normal symmetry with well-formed cerebral hemispheres and cerebellum ([figure 2A](#F2){ref-type="fig"}). On gross examination, white matter was slightly reduced, but demonstrated normal appearance without gray discoloration or cavitation. The lateral ventricles and cerebellum had normal size ([figure 2B](#F2){ref-type="fig"}), and corpus callosum thickness was normal for age.

![Neuropathology of the POLR3-HLD severe phenotype (patient 2)\
(A--B) Macroscopic appearance of the (A) right cerebral hemisphere, and (B) coronal sections showing a slight decrease of the volume of the white matter without appreciable ventricular enlargement. (C) Luxol fast blue--cresyl violet (Klüver-Barrera) staining demonstrating areas of poor myelination in the parietal white matter, but a normally myelinated corpus callosum. (D) Higher magnification of poorly myelinated white matter (10×), and (E) GFAP IHC revealing astrocytic gliosis (20×). (F) IBA1 IHC revealing activated microglia of the occipital white matter (10×). (G--I) Hemalun-phloxin staining revealing abnormalities of the putamen including (G) enlarged Virchow-Robin spaces (10×), (H) neuronal loss and gliosis with few calcifications (20×), and (I) neuronal death (60×). (J) Luxol fast blue--cresyl violet--stained section of the cerebellum revealing hypomyelination of the cerebellar white matter surrounding the dentate nucleus. (K) GFAP IHC demonstrating gliosis in the cerebellar white matter (20×), and (L) IBA1 IHC revealing activated microglia (10×). GFAP = glial fibrillary acidic protein; IHC = immunohistochemistry.](NG2019012377f2){#F2}

Histologic analysis of the neocortex and hippocampus revealed some ischemic neurons because of the final hypoxic-ischemic injury preceding death. No mineralization of cortical neurons or evidence of inflammatory infiltrate, necrosis, or microglial nodules was present.

White matter demonstrated patchy areas of rarefaction with mild myelin pallor. Oligodendrocytes showed normal morphology and density in all studied areas, including pale areas, and features of demyelination were absent. White matter also exhibited diffuse astrocytic gliosis, both chronic (fibrillary) and subacute (protoplasmic), with activation of microglia but without macrophagic changes associated with phagocytic activity ([figure 2, C--F](#F2){ref-type="fig"}). Changes in white matter appeared more severe in the parietal lobes ([figure 2, C--D](#F2){ref-type="fig"}). No Rosenthal fibers or axonal spheroids were seen. Immunohistochemistry did not reveal any axonal lesions. The corpus callosum and corticospinal tracts demonstrated normal myelination.

Cellular vacuolization was seen in the thalamus and basal ganglia. Atrophy of the putamen was evident with enlarged Virchow-Robin spaces and severe neuronal loss, associated with both chronic and subacute diffuse gliosis, along with rare calcifications and considerable activation of microglia ([figure 2, G--I](#F2){ref-type="fig"}). Discrete neuronal loss was evident in the caudate. Within the pallidum, numerous pale nuclei of Alzheimer type II glia were present due to the terminal anoxia, and no appreciable neuronal loss was evident. The adenohypophysis did not demonstrate pathologic abnormalities.

Hemisections of the brainstem demonstrated mild to moderate pyknosis in the pons and olivary nuclei of the medulla, consistent with acute ischemic changes. Patchy areas of reduced myelin were seen in the brainstem. The cerebellum demonstrated severe lesions of poorly myelinated white matter, with diffuse and mainly chronic (fibrillary) gliosis, but without notable morphological changes in oligodendrocytes ([figure 2, J--L](#F2){ref-type="fig"}). The cerebellar cortex and dentate nucleus appeared normal, and Bielschowsky staining did not reveal clear evidence of decreased axons. Moderate pyknosis was seen in Purkinje cells; however, there was no appreciable loss of neurons. In the spinal cord, patchy areas of reduced myelin were noted.

Genetic findings {#s2-4}
----------------

Each patient harbored a specific combination of compound heterozygous variants, including a variant causing a premature stop codon on one allele (P1: c.2119C\>T/p.Q707\*, P2: c.1681C\>T/p.R561\*, P3&4: c.1051C\>T/p.R351\*, P5: c.601delA/p.I201Lfs\*18, P6: c.3583delG/p.D1195Ifs\*47) and a specific intronic splicing variant on the other (P1-6: c.1771-7C\>G). We hypothesized that this splicing variant was leaky as complete absence of POLR3A is incompatible with life. PCR amplification using complementary DNA from fibroblasts of P2 revealed 2 additional bands compared with controls ([figure 3](#F3){ref-type="fig"}, figure e-1, [links.lww.com/NXG/A257](http://links.lww.com/NXG/A257)). Sequencing of bands revealed the presence of 2 aberrant transcripts resulting from abnormal splicing, including one lacking exon 14 causing a frameshift and premature stop codon (p.P591Mfs\*9) and the other lacking exons 13--14 causing loss of amino acids 548--637 (p.G548_Y637del). In addition, sequencing of the band corresponding to complementary DNA of wild-type length revealed the presence of both the nonsense transcript (c.1681C\>T/p.R561\*) and wild-type transcript, confirming the splice site variant is leaky ([figure 3B](#F3){ref-type="fig"}). Thus, 4 transcripts were detected, with sequences corresponding to (1) wild-type, (2) the nonsense variant, and those resulting from aberrant splicing events including (3) lack of exon 14, and (4) lack of both exons 13--14 ([figure 3C](#F3){ref-type="fig"}).

![Molecular and protein level implications of pathogenic variants in patient 2\
(A) Sanger sequencing results of RT-PCR products generated from patient 2 fibroblasts, as visualized by agarose gel electrophoresis in (B), in which 3 separate bands were excised and sequenced. In band 1, the presence of the *POLR3A* wild-type transcript is detected, as well as the transcript containing the paternally inherited nonsense variant (c.1681C \> T; p.R561\*), confirming that the splice site variant is leaky. Sequencing of the 2 additional bands confirms that the maternally inherited splice site variant (c.1771-7C\>G) causes production of 2 additional transcripts, including 1 transcript with a deletion of exon 14, which produces a new open reading frame that results in a premature stop codon (p.P591Mfs\*9), and the other containing a deletion of exons 13--14, which leads to the loss of amino acids 548--637 (p.G548_Y637del). (B) RT-PCR products with primers in *POLR3A* exons 11 and 15 revealing 2 additional bands in patient 2 fibroblasts compared with control fibroblasts. Cycloheximide treatment shows a stabilization of the mRNA containing the nonsense variant (band 1), confirming that it is targeted by NMD. β-Actin is shown as a loading control. (C) Schematic summary of each transcript detected following mRNA splicing. The starred region in the wild-type transcript denotes the POLR3A antibody epitope spanning from amino acids 607--698 for the immunoblots depicted in (D). (D) Immunoblots of protein lysates from frozen brain tissue of patient 2 (age 13 months) compared with that of an age/sex-matched control (age 14 months). Samples were collected from the subcortical white matter (left) and the cortical gray matter (right). (E) Normalized expression of POLR3A in the brain of patient 2 compared to that in the control. Chemiluminescent intensity of the POLR3A signal at 164 kDa was normalized to the intensity of the β-tubulin signal at 51 kDa for each blot. Average values of normalized protein expression are derived from 4 Western blot replicates, and error bars represent standard error of the mean. Full-length POLR3A is detected in both control and patient 2 white and gray matter, with decreases seen in patient samples compared with the control. bp = base pairs; CHX = cycloheximide; Del = deletion; Ex = exon; mRNA = messenger RNA; NMD = nonsense medicated decay; P2 = patient 2; RT-PCR = reverse transcription PCR; WT = wild type.](NG2019012377f3){#F3}

As transcripts containing nonsense variants are typically targeted for NMD, we hypothesized that the c.1681C\>T/p.R561\* variant transcript was subjected to degradation. We evaluated the presence of NMD in P2 fibroblasts compared with a control using cycloheximide, a compound that inhibits transcriptional elongation and consequently NMD. Following cycloheximide treatment, an increase in band 1 (corresponding to the wild-type transcript and nonsense variant transcript) was observed by semiquantitative PCR ([figure 3B](#F3){ref-type="fig"}), indicating that the nonsense transcript is subjected to NMD under normal conditions.

Because complete lack of POLR3A is incompatible with life, we sought to determine whether the detected residual wild-type transcript would lead to wild-type protein expression. We performed immunoblot analysis on protein extracts from frozen brain tissue of P2 and an age/sex-matched control. To ensure detection of only wild-type full-length protein, we chose a POLR3A antibody with an epitope spanning amino acid residues 607--698. In P2, this antibody cannot bind to the abnormal protein products as the epitope binds to residues located in the truncated POLR3A region, i.e., after the premature stop codon (p.R561\*) and contained/semicontained in the deleted residues resulting from the splicing variant (p.P591Mfs\*9, p.G548_Y637del). Thus, this antibody only allows detection of wild-type POLR3A ([figure 3C](#F3){ref-type="fig"}, figure e-1, [links.lww.com/NXG/A257](http://links.lww.com/NXG/A257)). We observed reductions in average normalized POLR3A levels both in brain gray matter (84.7% reduction, 95% CI = 69.3%--100%, d = 1.28) and white matter (54.8% reduction, 95% CI = 20.1%--89.5%, d = 1.34) of P2 compared with control ([figure 3, D and E](#F3){ref-type="fig"}). Gray matter displayed a greater reduction in POLR3A compared with white matter (average difference 29.9%; 95% CI = 0.7%--59.0%; d = 1.77).

Discussion {#s3}
==========

Here, we present an expanded spectrum of POLR3-HLD through description of 6 patients with a very severe phenotype and similar genotype. The dramatic clinical presentation, including prominent feeding and breathing difficulties and early death in 4 patients, is strikingly different from the typical POLR3-HLD phenotype. A large phenotypic study of POLR3-HLD revealed typical onset at age 3--4 years with mild to moderate motor delay and/or regression.^[@R1]^ Dysphagia and respiratory insufficiency were late findings. Death typically occurred in adulthood, where the youngest to die was aged 8 years.^[@R1]^

The MRI pattern associated with this phenotype is distinct; despite very severe clinical manifestations, all patients had notably more myelin with different imaging features than typical POLR3-HLD. An evolving change in signal pattern was seen in the lentiform nuclei, with thalami atrophy, progressing to more diffuse basal ganglia atrophy. This correlated with the prominent basal ganglia and thalami pathologic abnormalities, including atrophy, calcifications, and severe neuronal loss in the putamina. Two patients also had red nuclei signal abnormalities. Recently, a similar MRI phenotype was described in patients with a c.1771-7C\>G or c.1771-6C\>G variant, in trans with a missense, nonsense, splice site, or synonymous variant.^[@R21],[@R22]^ Clinical severity varied according to the trans *POLR3A* variant; patients homozygous for the splicing variant typically displayed a milder phenotype, whereas those harboring a trans loss of function variant displayed severe features with early onset.^[@R21][@R22][@R24]^ Of interest, patients homozygous or compound heterozygous for the c.1771-7C\>G and/or c.1771-6C\>G variants did not display white matter involvement and were described as only having the neuronal MRI features, including striatal involvement with caudate nucleus and putamen atrophy, and occasional red nuclei signal abnormalities.^[@R21][@R22][@R24]^ We hypothesize that these specific splicing variants cause a cell-specific effect (i.e., basal ganglia neurons) compared with other POLR3-HLD variants. This could explain why, when this variant is combined with a loss of function allele, patients with a severe phenotype have a specific MRI pattern (i.e., more myelin than the typical phenotype, with progressive basal ganglia involvement).

Neuropathologic examination revealed areas of reduced myelin in the brainstem. On MRI, all studies but one showed evidence of decreased myelin in specific posterior-inferior brainstem structures. Wallerian degeneration affecting specific tracts could at least partly explain these findings, although no clear axonal loss was documented on postmortem studies. The dentate nuclei appeared normal on neuropathologic analyses, consistent with the MRI pattern of preservation of the dentate nuclei and peridentate region. On MRI, reduced myelin was restricted to the hilus.

Although it is well known that hypomyelination is not obligate in POLR3-HLD,^[@R18],[@R25]^ the discrepancy between the relatively mild insufficient myelin deposition and the diffuse supratentorial atrophy was highly unusual and consistent across all MRIs. Although previous studies have revealed that oligodendrocytes are primarily affected in the typical form of POLR3-HLD,^[@R1],[@R26]^ our patients\' MRI and pathologic findings support the hypothesis that the severe form is primarily neuronal, with associated myelination deficits. We hypothesize that the pathophysiology associated with the severe phenotype varies substantially from typical POLR3-HLD and involves several neural cell types. As myelination is a complex process involving a multitude of signaling events between neurons and glia, it is possible that an increased disruption of POLR3 activity, or the production of aberrant transcripts, could manifest adversely in more cell types than in a milder deficit. It is known that dysregulation of transcription and translation-related genes is often associated with neurologic involvement, highlighting the importance of precise protein expression regulation during neural development.^[@R27][@R28][@R30]^ For example, defects in genes encoding aminoacyl-tRNA synthetases cause a variety of phenotypes, ranging from hypomyelination to brain malformations.^[@R31][@R32][@R38]^

Given the broad clinical spectrum of phenotypes associated with POLR3 deficiency, it is clear that pathogenic variants in POLR3 genes have distinct effects on various cellular processes.^[@R25],[@R39]^ Variants in *POLR3A* have been associated with phenotypes ranging from spastic ataxia--related disorders to neonatal progeroid syndrome, whereas variants in *POLR3B* have been associated with isolated hypogonadotropic hypogonadism, without hypomyelination or hypodontia, and a distinct phenotype of cerebellar hypoplasia with endosteal sclerosis.^[@R25],[@R39][@R40][@R41]^

In contrast to this extremely severe clinical presentation, we also identified 3 adults with a very mild phenotype and the same homozygous pathogenic *POLR3B* variant (c.1568T\>A/p.V523E) in our patient cohort. These patients were all diagnosed incidentally in adolescence/adulthood, based on brain MRI performed for unrelated reasons, or through genetic investigation of typical POLR3-HLD affected relatives. They had minimal findings on neurologic examination, if any, and MRI revealed milder findings than usually seen in POLR3-HLD. Two were previously described as having the mildest phenotype in a past large cohort study of POLR3-HLD,^[@R1]^ and the third, who has not been reported, is an adult woman in her late 70s for whom limited information is available. She is currently still ambulatory, and was able to reproduce, making it unlikely she had fertility concerns due to hypogonadotropic hypogonadism. She is described as having mild intellectual challenges and hearing loss from childhood of unknown etiology. She is also independent for all activities of daily living and maintained an active role in the care of her offspring. These cases highlight the extreme variability in disease severity of POLR3-HLD, which can range from very mild to exceptionally severe.

Each patient with a severe clinical presentation had a similar genotype, including a premature stop codon on one allele and a specific splicing variant (c.1771-7C\>G) on the other. In our patient, we demonstrated that this variant is leaky and causes alternative splicing events producing 2 aberrant transcripts, corresponding to results in a past study that investigated this variant in homozygous form.^[@R25]^ It is thought that this variant creates a new enhancer binding site, and competition for enhancer binding at either the native acceptor splice site (SRp40 enhancer protein) or aberrant binding site (SC35 enhancer protein) is likely the cause of incomplete inactivation of the native acceptor splice site and leaky production of the wild-type transcript.^[@R23],[@R25]^ We also confirmed that the transcript containing the nonsense variant was degraded by NMD. Moreover, as POLR3 is a housekeeping gene, complete loss of its function is incompatible with life, which is further supported by the embryonic lethal *Polr3a* knock-out mouse.^[@R42]^ Thus, leaky expression of some wild-type protein is not unexpected as all patients with a severe phenotype survived until early childhood. Although we were able to detect the production of some wild-type POLR3A protein in brain tissue of P2, protein levels were significantly decreased, supporting the hypothesis that minimal production of POLR3A is insufficient for proper neurodevelopment and growth. Less POLR3A protein was detected in gray matter compared with white matter, lending further support to our hypothesis that the severe phenotype is a primarily neuronal disorder.

These findings illustrate an expanded phenotypic spectrum of POLR3-HLD through presentation of patients with biallelic pathogenic variants in *POLR3A* and an extremely severe phenotype. Identifying genotype-phenotype relationships advances our understanding of the disease course, providing valuable information for clinicians and allowing patients and families to have proper genetic counseling. Our functional and pathologic studies shed light on the pathogenesis of the severe form of POLR3-HLD, opening the door for the development of targeted disease interventions.
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